WO2002020030A2 - Use of buchu extracts for hypertension - Google Patents
Use of buchu extracts for hypertension Download PDFInfo
- Publication number
- WO2002020030A2 WO2002020030A2 PCT/ZA2001/000136 ZA0100136W WO0220030A2 WO 2002020030 A2 WO2002020030 A2 WO 2002020030A2 ZA 0100136 W ZA0100136 W ZA 0100136W WO 0220030 A2 WO0220030 A2 WO 0220030A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- buchu
- fractions
- oil
- inflammatory
- vitamin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Definitions
- This invention relates to a composition of matter which is useful in the treatment of hypertension and inflammatory conditions
- Inflammation and hypertension are two well known conditions and it is not considered necessary to explain, in a patent specification, the medical reactions responsible for the hypertensive and inflammatory conditions.
- oil of buchu (Barosma betuliona or agosthoma betulina or agosthoma crenulata) has been used as an anti -inflammatory agent, usually in the form of a tea prepared from the leaves of the plant.
- a composition for the treatment of inflammatory and/or hypertensive conditions includes one or more fractions of the vacuum steam distillation of buchu oil, whether as the raw product obtained directly from the plant or as a residue from a process aimed at the separation of fractions for other purposes , the fraction/s comprising those rich in one or more of diphenol, diosmin, quercetin and rutin. Hesperidin and Vitamin B and E may also be present in substantial quantities.
- fractions are determined by experimentation and it has surprisingly been shown that such fractions exhibit an action far in excess of other fractions.
- the fraction/s exhibit unexpected action on neutrophil and monocyte functions; whereas as an anti-hypertensive agent the administration leads to unexpectedly good normalisation of blood pressure without any need for additional medication. This may be due to the increased secretion of renin by the kidneys.
- the invention also extends to a method of manufacturing a composition useful in the treatment of inflammatory and/or anti-hypertensive conditions, comprising the steps of selecting one or more fractions of the vacuum stream distillation of buchu oil, the fractions being rich in diphenol, diosmin, quercetin and rutin.
- the neutrophils Upon activation by complement peptides, the neutrophils up-rcgulatc the expression of the adhesion molecules on their surfaces in order to adhere more efficiently to the celJ wall of the bacteria and endothelial cells. These adhesion molecules are called the ⁇ -
- Integrins There are 2 that are present on the cell surfaces of neutrophils and both are expressed constitutionally but up regulated (expressed more) upon activation: the so- called LFA-1 (CDl la CD18 heterodimer) and the Mac-1 (CDllb/CD18 hetero imer). Both of these surface molecules can be measured and quantified by means of flow cytometry (a specialized technique that measures the amount of binding which takes place between the antibody specific for these molecules and the cell in question).
- Heparinised blood from healthy volunteers was obtained in vacuutainer tubes.
- the donating volunteers were not on any anti-hiflammatory medication.
- An aliquot of whole blood was pre-incubated (20 minutes at room temperature) with various dilutions of the 25 Buchu essential oil distillate prior to being stimulated using PMA (phorbol myristate acetate, an activator used in vitro).
- PMA phorbol myristate acetate, an activator used in vitro
- the neutrophils When the neutrophils arrive at the site of infection, they eat the organisms invading the host and once inside the cytoplasm of the cells, activate a series of enzymes on the inside of the membrane to generate toxic oxygen radicals. This is referred to as the oxygen- dependent killing mechanism.
- This respiratory burst can be measured by using fluorochrom.es which change colour when in the presence of the oxygen radicals generated. This change can be quantified by flow cytometry,
- a commercial kit (BurstTest) was used to measure the ability of neutrophils to mount a respiratory burst. For this, blood was obtained from healthy volunteers as above. The aliquots were pre-incubated with dilutions of the Buchu oils prior to being activated with whole bacteria (included in the commercial kit) and processed further.
- the experimental outline was as follows:
- the red blood cells were lysed and ihe non- lysed cells washed and analysed on a flow cytometry. The % positive cells as well as the MCF measured. Fifteen thousand events were accumulated for the analysis.
- monocytes When activated, monocytes release IL6 and TNF- ⁇ that are responsible for the recruitment of other immune cells and initiate a self-perpetuating chronic inflammatory process. These factors can be quantified by activating monocytes with bacterial products (endotoxin) and measuring the soluble factors by immunological assays (KL1SA) using specific antibodies. The aims of these experiments were to measure the release of 1L6 in the following way. Whole blood was collected into vacuutainer tubes and the mononuclcar cells isolated by density centrifugaiion. The monocyte rich fraction was obatincd by adherence to the wells of a multi-well culture plate. The adherent cells were stimulated to release the monokine IL6 by being activated by a pre-detcrmincd concentration of bacterial endotoxin (Lipopolysaccharide). The experimental outline was. as follows:
- the cells were incubated for 17 hours at 37°C and 5% CG 2 .
- the absolute concentrations of IL ⁇ 5 in the respective supernatants were calculated from a standard curve derived from the standards, The results were expressed as Units of IL6 (pg/ml) released by the respective culture wells.
- the neutrophils pre-incubated with the various dilutions of Buchu oil distillate showed a statistically significant decrease in their ability to express the MAC-1 adhesion molecules as measured by flow cytometry.
- the cells when the cells arc activated by PMA, they increase their expression of MAC-1 (compare negative control versus positive control).
- the expression is significantly inhibited (p ⁇ 0.05) by diltions of 1 :400; 1 :800 and 1 : 1600. Thereafler, the inhibitory effects are diluted out. TMs effect was not paralleled by the monocytes under identical conditions of culture.
- Figure 1 Expression of MAC-1 (CDllb/CD18) by Neutrophi ⁇ es and monocytes post activation in the presence/absence of Buchu oil distillate at different dilutions:
- Figure 2 The effects of different oil distillates at the same dilution (1 :400) on the expression of MAC-1 (CDllb/CDlS) on neutrophils and mo ⁇ ocytes post-act ⁇ valion by PMA:
- oxygen radicals arc protective when tliis is generated in Ihe cytoplasm of the cell in that it kills the bacterium. However, when these are released to the external medium, it can damage healthy tissues in the vicinity of the phagocytic cell
- the cellular infiltrate made up primarily of monocytes and other monouclear cells release 1L6, a factor with varied biological activities including fever, pain, calcium mobilization from bone, etc This factor perpetuates the on-going inflammation and thus is pivotal in the tissue damage seen in these chronic conditions
- Mrs GK suffered from high blood pressure for several years (4 years) necessitating medication which could not control this chronic condition.
- Several changes of her medication still did not manage to control her blood pressure which stood at 220/120.
- she was introduced to the Buchu water.
- her hypertension has been controlled at 145/80 without any other medication for this serious condition.
- This patient was diagnosed with a blood pressure of 160/95 and at other times 170/100. She was prescribed various medications that caused side effects and she was advised to stop the medication. She discovered the Buchu water product and since using the product, her condition improved: her blood pressure now stands at 130/75. She has since never shown signs of her previously chronic high blood pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002425912A CA2425912A1 (en) | 2000-09-11 | 2001-09-07 | Use of buchu extracts for hypertension |
EP01977948A EP1318826A2 (en) | 2000-09-11 | 2001-09-07 | Use of buchu extracts for hypertension |
AU2001297027A AU2001297027B2 (en) | 2000-09-11 | 2001-09-07 | Use of buchu extracts for hypertension |
AU9702701A AU9702701A (en) | 2000-09-11 | 2001-09-07 | Use of buchu extracts for hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200004785 | 2000-09-11 | ||
ZA2000/4785 | 2000-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002020030A2 true WO2002020030A2 (en) | 2002-03-14 |
WO2002020030A3 WO2002020030A3 (en) | 2002-12-27 |
Family
ID=25588902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ZA2001/000136 WO2002020030A2 (en) | 2000-09-11 | 2001-09-07 | Use of buchu extracts for hypertension |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1318826A2 (en) |
AU (2) | AU9702701A (en) |
CA (1) | CA2425912A1 (en) |
WO (1) | WO2002020030A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3987C2 (en) * | 2009-09-03 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency |
MD3986C2 (en) * | 2009-09-23 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of portal gastropathies in the hepatic cirrhosis |
US7833962B2 (en) | 2003-07-31 | 2010-11-16 | Conopco, Inc. | Method of reducing hypertension by administering flavanol gylcosides |
ITGE20100040A1 (en) * | 2010-04-22 | 2011-10-23 | Bioway Di Patrucco Claudio | HERBORISTIC AND FOOD PREPARATION FOR PROTECTIVE AND TONING ACTION OF ORGANS OF THE GENITO-URINARY SYSTEM BOTH FEMALE AND MALE, AND HAVING AN ADDITIONAL EFFECT FOR CHILDREN'S RE-BALANCING |
MD4232C1 (en) * | 2012-11-08 | 2014-01-31 | Георге АНГЕЛИЧ | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure |
MD4231C1 (en) * | 2012-11-08 | 2014-01-31 | Георге АНГЕЛИЧ | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis |
WO2016088030A1 (en) * | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Buchu preparations |
WO2016088028A1 (en) | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Anti-viral therapeutic compositions |
WO2016088029A1 (en) * | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Therapeutic compositions |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020053750A1 (en) * | 2018-09-10 | 2020-03-19 | Cape Kingdom Nutraceuticals Pty Ltd | Pre-diabetic therapeutic composition |
WO2020053751A1 (en) * | 2018-09-10 | 2020-03-19 | Cape Kingdom Nutraceuticals Pty Ltd | Anti-obesity therapeutic composition |
-
2001
- 2001-09-07 CA CA002425912A patent/CA2425912A1/en not_active Abandoned
- 2001-09-07 WO PCT/ZA2001/000136 patent/WO2002020030A2/en active Search and Examination
- 2001-09-07 AU AU9702701A patent/AU9702701A/en active Pending
- 2001-09-07 EP EP01977948A patent/EP1318826A2/en not_active Withdrawn
- 2001-09-07 AU AU2001297027A patent/AU2001297027B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
DATABASE FSTA [Online] INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANFURT/MAIN, DE; FUCHS S ET AL: "Monoterpene biosynthesis in Agathosma crenulata (Buchu)." Database accession no. 2001-00-t0513 XP002206871 & FLAVOUR AND FRAGRANCE JOURNAL 16 (2) 123-135 2001 CORRESPONDENCE (REPRINT) ADDRESS, A. MOSANDL, INST. FUER LEBENSMITTELCHEM., JOHANN WOLFGANG GOETHE-UNIV. FRANKFURT, 60439 FRANKFURT (MAIN), GERMANY. E-MAIL MOSANDL(A)EM.UNI-FRANKFURT.DE, * |
ROMAN KAISER ET AL.: "ANALYSIS OF BUCHU OIL" JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY., vol. 23, no. 5, 1975, pages 943-950, XP002206870 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0021-8561 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833962B2 (en) | 2003-07-31 | 2010-11-16 | Conopco, Inc. | Method of reducing hypertension by administering flavanol gylcosides |
MD3987C2 (en) * | 2009-09-03 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency |
MD3986C2 (en) * | 2009-09-23 | 2010-07-31 | Георге АНГЕЛИЧ | Use of Diosmine for the treatment of portal gastropathies in the hepatic cirrhosis |
ITGE20100040A1 (en) * | 2010-04-22 | 2011-10-23 | Bioway Di Patrucco Claudio | HERBORISTIC AND FOOD PREPARATION FOR PROTECTIVE AND TONING ACTION OF ORGANS OF THE GENITO-URINARY SYSTEM BOTH FEMALE AND MALE, AND HAVING AN ADDITIONAL EFFECT FOR CHILDREN'S RE-BALANCING |
MD4232C1 (en) * | 2012-11-08 | 2014-01-31 | Георге АНГЕЛИЧ | Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure |
MD4231C1 (en) * | 2012-11-08 | 2014-01-31 | Георге АНГЕЛИЧ | Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis |
WO2016088030A1 (en) * | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Buchu preparations |
WO2016088028A1 (en) | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Anti-viral therapeutic compositions |
WO2016088029A1 (en) * | 2014-12-01 | 2016-06-09 | Cape Kingdom Nutraceuticals (Pty) Ltd | Therapeutic compositions |
EP3226880A4 (en) * | 2014-12-01 | 2018-08-29 | Cape Kingdom Nutraceuticals (Pty) Ltd. | Buchu preparations |
Also Published As
Publication number | Publication date |
---|---|
CA2425912A1 (en) | 2002-03-14 |
EP1318826A2 (en) | 2003-06-18 |
AU9702701A (en) | 2002-03-22 |
WO2002020030A3 (en) | 2002-12-27 |
AU2001297027B2 (en) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6379714B1 (en) | Pharmaceutical grade botanical drugs | |
Garcia-Velasco et al. | Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis | |
RU2687498C2 (en) | Algae extract for use as immunomodulatory agent | |
AU2001297027B2 (en) | Use of buchu extracts for hypertension | |
JPH06172183A (en) | Medicinal composition | |
Sela et al. | Allicin inhibits SDF‐1α‐induced T cell interactions with fibronectin and endothelial cells by down‐regulating cytoskeleton rearrangement, Pyk‐2 phosphorylation and VLA‐4 expression | |
Hersey et al. | Tumour‐related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients | |
AU2001297027A1 (en) | Use of buchu extracts for hypertension | |
Roszman et al. | Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor | |
Lee et al. | Suppression of the onset and progression of collagen‐induced arthritis by chebulagic acid screened from a natural product library | |
JP4010768B2 (en) | A new pectic polysaccharide purified from Angelica, Gigas and Nakai, its purification method and its use as an immunostimulant | |
Seow et al. | In vitro immunosuppressive properties of the plant alkaloid tetrandrine | |
KR20000053988A (en) | Pharmacolocial effect and extracting method for osteoporosis and rhematoid arthritis treatment by constituent drugs of oriental medicine | |
JP2004307458A (en) | Galenical composition having anticancer/immune/hematopoietic function enhancing effect and oxidative living body damage suppressing effect and manufacturing method thereof | |
Stein et al. | Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro | |
Oh et al. | Histamine synthesis by non-mast cells through mitogen-dependent induction of histidine decarboxylase. | |
WO1998030583A1 (en) | Complexes and combinations of fetuin with therapeutic agents | |
EP0607296A1 (en) | Use of misoprostol for the treatment of late-phase allergy | |
WO2019055513A1 (en) | Inhibited expression of pd-l1 and enhanced expression of pd-1 | |
US20080262080A1 (en) | Allergy Suppressive Agent | |
KR100506396B1 (en) | The pharmaceutical composition and its preparation method of herb mixture for cancer inhibition, recovery of immune system and protection of body from oxidative damage | |
US20120003178A1 (en) | Evaluating the therapeutic potential of a glucan | |
Miyake et al. | Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis | |
Bonavida et al. | Multistage model of natural killer cell-mediated cytotoxicity involving NKCF as soluble cytotoxic mediators | |
EP2857068A1 (en) | Fractions of liquorice extracts depleted of glycyrrhizic acid and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001297027 Country of ref document: AU Ref document number: 2425912 Country of ref document: CA Ref document number: 2001977948 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 417/MUMNP/2003 Country of ref document: IN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |